心室成纤维细胞条件培养液促进成纤维细胞胶原合成和增殖

采用心室成纤维细胞条件培养液培养心室成纤维细胞,通过测定[^3H]－脯氨酸（[^3H]－proline）的掺入率来了解心室成纤维细胞总胶原合成速率,通过测定[^3H]－胸腺嘧啶核苷（[^3H]－TdR）的掺入率以及c-fos基因的表达丰度来了解心室成纤维细胞的增殖速率。结果显示：心室成纤维细胞条件培养液（FCGM）能增加细胞自身的[^3H]－proline的掺入率和[^3H]－TdR的掺入率,并具有剂量依赖性;FCGM也能促进细胞自身c-fos基因的表达,刺激后1h达高峰。ETA受体拮抗剂BQ123能部分阻断FCGM增加成纤维细胞胶原合成的增殖作用,而AT1受体拮抗剂CV11974和α肾上腺素受体拮抗剂regitin无此效果。结果提示：心室成纤维细胞具有自分泌功能,能分泌内皮素等生物活性物质,促进成纤维细胞胶原的合成和增殖。     

β-肾上腺素受体激动对新生大鼠心肌细胞代谢的影响

为了观察β-肾上腺素受体(β-AR)持续激动对心肌细胞代谢的影响,本工作以培养的新生大鼠心肌细胞为研究对象,采用[^3H]-亮氨酸([^3H]-leucine)掺入法和BCA蛋白分析法检测心肌细胞的蛋白合成代谢与蛋白含量,[^3H]-2-脱氧-D-葡萄糖摄取测定方法检测心肌细胞对葡萄糖的摄取量,并采用蛋白免疫印迹杂交方法检测腺苷酸活化蛋白激酶(adenosine monophosphate activated protein kinase,AMPK)磷酸化程度。结果显示,β-AR激动剂异丙肾上腺素(isoproterenol,ISO)持续刺激心肌细胞48h,心肌细胞[^3H]-leucine掺入量和蛋白质含量与对照组相比均无显著差异。用ISO或去甲肾上腺素(α1-AR特异性拮抗剂哌唑嗪存在下)持续激动β-AR 48h,心肌细胞的葡萄糖摄取量和AMPK磷酸化均显著高于对照组。上述结果表明,β-AR持续激动对培养的新生大鼠心肌细胞蛋白质合成及蛋白质含量没有明显的作用,但可引起葡萄糖摄取量明显增加和AMPK的激活,提示β-AR可能与心肌肥厚过程中能量代谢状态的变化有关。     

MKP-1在血管紧张素Ⅱ导致心肌肥大反应中的调控作用

本研究主要从丝裂原活化蛋白激酶磷酸酶 1(MKP 1)角度 ,研究丝裂原活化蛋白激酶 (MAPK)信号途径在血管紧张素Ⅱ介导的新生大鼠心肌细胞肥大反应中的作用及调控机制。实验以心肌细胞蛋白合成速率、蛋白含量及细胞表面积作为心肌肥大反应的指标 ,以凝胶内MBP原位磷酸化测定MAPK活性 ,以免疫印迹法 (Westernboltting)分别测定MKP 1及磷酸化p44MAPK、p42MAPK蛋白表达。结果发现 :(1)AngⅡ (10 -7mol/L)处理 48h ,心肌细胞 3H 亮氨酸掺入率、蛋白含量及细胞表面积明显增加 ,AngⅡ增加 3H 亮氨酸掺入的作用可被血管紧张素Ⅱ 1型受体 (AT1受体 )拮抗剂CV11974(10 -6mol/L)明显抑制 (抑制 85 % ) ,被MAPK激酶 (MEK)特异性抑制剂PD0 980 5 9(5× 10 -5mol/L)部分抑制 (抑制 32 5 % ) ;(2 )CV11974或PD0 980 5 9可明显抑制AngⅡ介导的磷酸化MAPK蛋白表达及MAPK酶活性 (以γ 32 P ATP掺入表示 ) ;(3)以磷酸化MAPK蛋白表达反映MAPK活性 ,可见AngⅡ处理心肌细胞5min ,MAPK活性即开始增加 ,30min左右达到高峰 ,2h后基本恢复正常 ;而MKP 1蛋白表达 30min即见增加 ,持续 2h以上 ;(4 )用放线菌素D (actinomycinD)处理心肌细胞 30min可明显抑制MKP 1的表达 ,同时使AngⅡ致磷酸化MAPK蛋白表达时间延长至 2h以上。以上结果     

肿瘤坏死因子-α诱导心肌肥大中CaN信号通路的作用

目的:研究钙调神经磷酸酶(CaN)信号通路在肿瘤坏死因子-α(TNF-α)诱导心肌细胞肥大中的作用。方法:Lowry法测心肌细胞蛋白含量;计算机图象分析系统测心肌细胞体积;[3H]-亮氨酸掺入法测心肌细胞蛋白合成;Till阳离子测定系统观察胞内[Ca2+]i瞬变;Western blot法测定CaN的表达。结果:①CaN特异性抑制剂CsA(0.2μmol/L)明显抑制TNF-α(100μg/L)诱导的心肌细胞蛋白含量、蛋白合成和细胞体积增大,但对正常心肌细胞生长无影响。②CaN特异性抑制剂CsA(0.2μmol/L)明显降低TNF-α诱导的心肌细胞内钙离子浓度([Ca2+]i)瞬变幅度增高。③TNF-α明显增强心肌细胞内CaN的表达。结论:TNF-α可能通过引起心肌细胞[Ca2+]i升高,促进CaN表达诱导心肌细胞肥大。     

新生大鼠心室成纤维细胞条件培养液的促心肌细胞肥大作用

利用新生大鼠心室成纤维细胞条件培养液孵育心肌细胞,证实成纤维细胞条件培养液能明显增大心肌细胞的表面积,增加心肌细胞的蛋白含量和「＾３Ｈ」－亮氨酸「＾３Ｈ」－Ｌｅｕ）的掺入,上述作用以第３天的条件培养液作用最强,具有剂量依赖性。ＥＴＡ受体拮抗剂ＢＱ１２３能部分阻断成纤维细胞条件培养液促进心肌细胞肥大的作用,而ＡＴ１受体拮抗剂ＣＶ１１９７４和α－肾上腺素受体拮抗剂ｒｅｇｉｔｉｎ却无此效果。结果提示：成     

雌激素对培养心肌细胞肥大和凋亡的抑制作用

目的研究生理剂量17β雌二醇(17-βestradiol,E2)对去甲肾上腺素(norepinephrine,NE)诱导的心肌细胞肥大和凋亡的影响。方法培养新生大鼠心肌细胞分别给予NE(50μmol)、E2(10nmol)、NE(50μmol) E2(10nmol)作用48h,通过心肌细胞蛋白质含量、[3H]亮氨酸掺入率检测心肌细胞肥大;透射电镜、DNA Ladder和流式细胞术检测心肌细胞凋亡。结果17β雌二醇可抑制去甲肾上腺素诱导的心肌细胞蛋白质含量、[3H]亮氨酸掺入率和心肌细胞凋亡率的增加,使凋亡心肌细胞特异性超微结构和DNA梯状带纹消失。结论17β雌二醇可抑制去甲肾上腺素所诱导的心肌细胞肥大和凋亡。     

ZFP580对大鼠心肌缺血/再灌注后心室重塑的影响

目的：探究锌指转录因子（ZFP580）与心肌缺血/再灌注损伤后心室重塑的关系。方法：72只SD大鼠随机分为假手术（sham）组（n=8）和心肌缺血/再灌注（I/R）组（n=64）,其中I/R组分别在再灌注后的0.5 h、1 h、2 h、4h、1 d,7 d,14 d,28 d处死后取材,观察心肌组织中ZFP580的表达。培养大鼠H9C2心肌细胞,每组设3个复孔,分别在转化生长因子β1（TGF-β1）刺激0 h、8 h、16 h、24 h后观察心肌细胞肥大情况,并检测心肌细胞中β-MHC、心房利钠肽（ANP）以及ZFP580 mRNA的表达。利用慢病毒介导的基因转染获得高表达ZFP580的H9C2心肌细胞,转染72h后,检测心肌细胞中基质金属蛋白酶3（MMP-3）的表达。结果：成功建立心肌缺血/再灌注损伤模型,大鼠心肌I/R损伤后第14天,心肌组织大面积梗死,心肌细胞呈嗜酸性变。大鼠心肌组织中ZFP580及TGF-β1表达上调。TGF-β1（5 ng/ml）刺激H9C2心肌细胞后诱导心肌细胞肥大,心肌细胞肥大标志蛋白β-MHC、ANP表达上调,且心肌细胞中ZFP580mRNA表达上调（P < 0.05）。高表达ZFP580的H9c2心肌细胞中MMP-3表达下调（P < 0.05）。结论：锌指转录因子ZFP580可能参与了心肌缺血/再灌注后心室重塑的过程,其作用可能与参与TGF-β1诱导的心肌细胞肥大过程以及抑制心肌细胞产生MMP-3有关。     

ESM-1预处理小鼠骨髓间充质干细胞的实验研究

目的:探讨小鼠骨髓间充质干细胞(Bone marrow-derived mesenchymal stem cells,MSCs)经不同浓度的内皮细胞特异性分子-1(Endothelial cell-specific molecule 1,ESM-1)干预后,对其分泌的细胞因子的影响。方法:选择不同浓度的ESM-1和不同干预时间,对MSCs进行预处理;分析其分泌的VEGF、ALP等代表细胞活性的细胞因子含量改变情况;明确ESM-1预处理MSCs所需的最佳干预浓度和最佳干预时间。结果:通过不同ESM-1浓度干预MSCs,其中H(0.55μg/mL ESM-1)组条件培养液中VEGF和ALP含量同最高,分别为(82.500±3.307)和(0.228±0.020)pg/mL,差异有统计学意义,P0.001。选择0.55μg/mL ESM-1对MSCs进行不同时间的干预,结果显示d(3 h)组条件培养液中VEGF含量最高,g(4.5 h)组ALP含量同最高,分别为(69.112±3.618)和(0.352±0.030)pg/mL,差异有统计学意义,P0.001。结论:不同干预因子预处理MSCs所需的最佳浓度和预处理时间不一。ESM-1对MSCs的最佳干预浓度为0.55μg/mL。不同组织细胞的细胞因子的表达和所受到的影响因素也不相同。     

骨髓间质干细胞向大鼠损伤心肌组织的迁移

实验旨在动态观察骨髓间充质干细胞（mesenchymal stem cells,MSCs）向不同微环境下心肌组织的迁移特点,明确组织损伤在干细胞迁移中的作用,为提高干细胞治疗的靶向性和高效性奠定初步试验基础。分离纯化雄性Sprague-Dawley（SD）大鼠的骨髓MSCs,输注入雌性SD大鼠。实验分为4组：正常大鼠＋MSCs移植组,假手术＋MSCs移植组,心肌缺血＋MSCs移植组,心肌缺血对照组（心肌缺血＋培养基移植）。结扎冠状动脉前降支制造心肌缺血模型,将相等数量的雄性MSCs经尾静脉注射移植入前3组雌性大鼠体内,对照组注射等体积培养基,分别于移植后1周及8周取心脏组织标本,采用荧光原位杂交方法（fluorescence in situ hybridization,FISH）检测大鼠Y染色体雄性鉴别基因sty片段的表达,用透射电镜观察大鼠心肌组织超微结构改变。结果发现,移植后1周和8周,正常大鼠移植组和对照组大鼠的心肌组织中均未见sry基因的表达,但假手术移植组和心肌缺血移植组的心肌组织中均可见sty基因的表达,心肌缺血移植组的Y染色体sty基因阳性细胞数量在两个时间点均显著高于假手术移植组（P〈0．01）。分别比较心肌缺血移植组和假手术组在移植后1周和8周的Y染色体sry基因阳性细胞的数量,两个时间点无明显差异。心肌组织的超微结构观察发现心肌缺血移植组大鼠的心肌梗死周边区域可见一些细胞,其形态类似于体外培养的MSCs。研究结果提示MSCs具有向损伤心肌组织迁移的特性,迁移的高峰期可能在组织损伤1周左右,组织损伤及其程度在干细胞迁移中起重要作用。     

细胞因子对GH3细胞中人生长激素基因表达的影响

为了研究细胞因子IL 11、睫状神经营养因子 (CNTF)和转化生长因子 (TGF β)对大鼠垂体GH3 细胞中人生长激素 (hGH)的基因启动子活性的影响及其与垂体特异性转录因子Pit 1蛋白的关系 ,首先建立含hGH基因启动子 (- 4 84～ 30bp)和荧光素酶融合基因的稳定转化GH3 细胞系 ,然后用细胞因子刺激 ,检测细胞培养液和细胞裂解液中GH的含量 ,反映它们对GH分泌和合成的影响 ;检测GH3 细胞内荧光素酶的变化 ,说明细胞因子对hGH基因启动子活性的作用。将Pit 1蛋白表达质粒 (pcDNA pit 1 cDNA)单独转染或与Pit 1反义寡核苷酸 (Pit 1OND)共转染于稳定转化的GH3 细胞中 ,观察加入细胞因子后荧光素酶的变化 ,探讨细胞因子的作用与Pit 1蛋白的关系。结果表明 ,IL 11(2 0nmol/L)、CNTF(10nmol/L)能刺激大鼠垂体GH3 细胞中GH的分泌和合成 ,增强GH3 细胞中荧光素酶的表达 ,分别增加到对照组的 12 6 %、136 %。TGF β(5nmol/L)能减少GH的分泌和合成 ,抑制荧光素酶的表达到对照组的 77%。Pit 1蛋白过表达和表达被抑制对细胞因子的调节作用没有影响。这说明IL 11、CNTF和TGF β可通过调节大鼠垂体GH3 细胞中hGH基因启动子活性影响GH的合成 ,Pit 1蛋白可能不参与这些调节作用。     

Specific LPA receptor subtype mediation of LPA-induced hypertrophy of cardiac myocytes and involvement of Akt and NFkappaB signal pathways

Lysophosphatidic acid (LPA) is a bioactive phospholipid with diverse functions mediated via G-protein-coupled receptors (GPCRs). In view of the elevated levels of LPA in acute myocardial infarction (MI) patients we have conducted studies aimed at identifying specific LPA receptor subtypes and signaling events that may mediate its actions in hypertrophic remodeling. Experiments were carried out in cultured neonatal rat cardiomyocytes (NRCMs) exposed to LPA and in a rat MI model. In NRCMs, LPA-induced hypertrophic growth was completely abrogated by DGPP, an LPA1/LPA3 antagonist. The LPA3 agonist OMPT, but not the LPA2 agonist dodecylphosphate, promoted hypertrophy as examined by 3[H]-Leucine incorporation, ANF-luciferase expression and cell area. In in vivo experiments, LPA1, LPA2 and LPA3 mRNA levels as well as LPA1 and LPA3 protein levels increased together with left ventricular remodeling (LVRM) after MI. In addition, LPA stimulated the phosphorylation of Akt and p65 protein and activated NF-kappaB-luciferase expression. Inhibitors of PI3K (wortmannin), mTOR (rapamycin), and NF-kappaB (PDTC or SN50) effectively prevented LPA-induced 3[H]-Leucine incorporation and ANF-luciferase expression. Furthermore, ERK inhibitors (U0126 and PD98059) suppressed LPA-stimulated activation of NF-kappaB and p65 phosphorylation whereas wortmannin showed no effect on NF-kappaB activation. Our findings indicate that LPA3 and/or LPA1 mediate LPA-induced hypertrophy of NRCMs and that LPA1 and LPA3 may be involved in LVRM of MI rats. Moreover, Akt and NF-kappaB signaling pathways independently implicate in LPA-stimulated myocardial hypertrophic growth.     

Modelling of myocardial hypertrophy in vitro for solving problems of medicinal correction

The work has been done on primary heart culture from neonatal rat ventricle. Cardiomyocyte hypertrophy was modelled using noradrenaline (NA), angiotensin II (AII) and fetal serum, respectively. Cell hypertrophy of primary heart cultures was assessed by measuring the surface area, the scope of protein synthesis estimated by 3H-leucine autoradiography and the contents of nucleic acids in gallocyanin-chromalum stained cardiomyocytes. The structure of myofibrillar apparatus was studied by rhodamine-conjugated phalloidin and indirect immunofluorescence of muscle alpha-actinin. Treatment with 10(-6) M NA increased 3H-leucine incorporation in 9-day old heart culture by 42% without changing cell size. AII in a dose 1 microM stimulated protein synthesis activity by 1.3 fold and the surface area by 1.7 fold, both in 2- and 9-day old primary heart cultures. The maximum stimulation of cell hypertrophy was provided by the medium supplemented with fetal serum. RNA contents in the cytoplasm of cardiomyocytes increased by 7.8 fold and the myocardial cell size by 2.9 fold in serum-supplemented culture by 9 days of cultivation. In the medium with fetal serum, amounts of cardiomyocytes with tetraploid nuclei reached 33%, against 14% in control. Coculturing of myocardiocytes and fibroblasts rendered effects of fetal serum on the growth of myocardiocytes. Cultivation in the presence of 1 microM enalapril, an ACE inhibitor, suppressed the development of cardiac muscle cells hypertrophy. The effect of enalapril depended on the degree of cellular hypertrophy. Addition of 10 microM amiloride to the medium lowered the protein synthesis by 29% independently on the initial cellular hypertrophy.     

MKP—1在血管紧张素Ⅱ导致心肌肥大反应中的调控作用

本研究主要从丝裂原活化蛋白激酶磷酸酶－１（ＭＫＰ－１）角度,研究丝裂原活化蛋白激酶（ＭＡＰＫ）信号途径在血管紧张素Ⅱ介导的新生大鼠心肌细胞肥大反应中的作用及调控机制。实验以心肌细胞蛋白合成速率、蛋白含量及细胞表面积作为心肌肥大反应的指标,以凝胶内ＭＢＰ原位磷酸化测定ＭＡＰＫ活性,以免疫印迹法（Ｗｅｓｔｅｒｎ ｂｏｌｔｔｉｎｇ）分别测定ＭＫＰ－１及磷酸化ｐ４４ＭＡＰＫ、ｐ４２ＭＡＰＫ蛋白表达。结果发     

Neuropeptide Y induces cardiomyocyte hypertrophy via calcineurin signaling in rats

Neuropeptide Y (NPY) has been shown to participate in cardiac hypertrophy. However, the mechanisms by which NPY induces cardiomyocyte hypertrophy are poorly understood. This study tested the hypothesis that NPY induces cardiomyocyte hypertrophy through Ca2+/CaM-dependent calcineurin (CaN) pathway in cultured neonatal rat cardiomyocytes. After 24-h treatment, NPY (100 nM) significantly increased 3H-leucine incorporation and c-Jun mRNA expression, concomitant with augment of CaN activity and protein level in cardiomyocytes compared to those cells without NPY treatment. The enhancement of 3H-leucine incorporation and c-Jun mRNA expression in cardiomyocytes treated with NPY were markedly inhibited by cyclosporine A (CsA), a selective inhibitor of CaN. We also investigated the effect of NPY on intracellular Ca2+ level in cardiomyocytes. There were no obvious changes in intracellular Ca2+ level of cytoplasm and nucleus in cardiomyocytes treated with NPY (100 nM) for 10 min. However, NPY significantly increased intracellular Ca2+ level of cytoplasm and nucleus in cardiomyocytes after 24-h treatment. The result suggested that NPY could induce hypertrophy of cardiomyocytes via Ca2+/CaM-dependent CaN signal pathway. The enhancement of [Ca2+]i caused by NPY may activate CaN signal pathways to mediate cardiac hypertrophy.     

Conditioned medium enhances the fusion capability of rat bone marrow mesenchymal stem cells and cardiomyocytes

Mesenchymal stem cells (MSCs) show accelerated regeneration potential when these cells experience hypoxic stress. This “preconditioning” has shown promising results with respect to cardio-protection as it stimulates endogenous mechanisms resulting in multiple cellular responses. The current study was carried out to analyze the effect of hypoxia on the expression of certain growth factors in rat MSCs and cardiomyocytes (CMs). Both cell types were cultured and assessed separately for their responsiveness to hypoxia by an optimized dose of 2,4,-dinitrophenol (DNP). These cells were allowed to propagate under normal condition for either 2 or 24 h and then analyzed for the expression of growth factors by RT-PCR. Variable patterns of expression were observed which indicate that their expression depends on the time of re-oxygenation and extent of hypoxia. To see whether the growth factors released during hypoxia affect the fusion of MSCs with CMs, we performed co-culture studies in normal and conditioned medium. The conditioned medium is defined as the medium in which CMs were grown for re-oxygenation till the specified time period of either 2 or 24 h after hypoxia induction. The results showed that the fusion efficiency of cells was increased when the conditioned medium was used as compared to that in the normal medium. This may be due to the presence of certain growth factors released by the cells under hypoxic condition that promote cell survival and enhance their fusion or regenerating ability. This study would serve as another attempt in designing a therapeutic strategy in which conditioned MSCs can be used for ischemic diseases and provide more specific therapy for cardiac regeneration.     

Mesenchymal Stem Cells Attenuate Peritoneal Injury through Secretion of TSG-6

Background

Mesothelial cell injury plays an important role in peritoneal fibrosis. Present clinical therapies aimed at alleviating peritoneal fibrosis have been largely inadequate. Mesenchymal stem cells (MSCs) are efficient for repairing injuries and reducing fibrosis. This study was designed to investigate the effects of MSCs on injured mesothelial cells and peritoneal fibrosis.

Methodology/Principal Findings

Rat bone marrow-derived MSCs (5 ×10⁶) were injected into Sprague-Dawley (SD) rats via tail vein 24 h after peritoneal scraping. Distinct reductions in adhesion formation; infiltration of neutrophils, macrophage cells; number of fibroblasts; and level of transforming growth factor (TGF)-β1 were found in MSCs-treated rats. The proliferation and repair of peritoneal mesothelial cells in MSCs-treated rats were stimulated. Mechanically injured mesothelial cells co-cultured with MSCs in transwells showed distinct increases in migration and proliferation. In vivo imaging showed that MSCs injected intravenously mainly accumulated in the lungs which persisted for at least seven days. No apparent MSCs were observed in the injured peritoneum even when MSCs were injected intraperitoneally. The injection of serum-starved MSCs-conditioned medium (CM) intravenously reduced adhesions similar to MSCs. Antibody based protein array of MSCs-CM showed that the releasing of TNFα-stimulating gene (TSG)-6 increased most dramatically. Promotion of mesothelial cell repair and reduction of peritoneal adhesion were produced by the administration of recombinant mouse (rm) TSG-6, and were weakened by TSG-6-RNA interfering.

Conclusions/Significance

Collectively, these results indicate that MSCs may attenuate peritoneal injury by repairing mesothelial cells, reducing inflammation and fibrosis. Rather than the engraftment, the secretion of TSG-6 by MSCs makes a major contribution to the therapeutic benefits of MSCs.     

Insulin-stimulated protein synthesis in submandibular acinar cells: interactions with adrenergic and cholinergic agonists

The effects of insulin and secretory agonists on amino acid incorporation into submandibular gland proteins were studied using isolated acinar cell aggregates. Insulin stimulated the incorporation of 3H-leucine into TCA-precipitable proteins in a rapid, dose-dependent manner (half-maximal response at 1 nM). Isoproterenol, a beta-adrenergic agonist, also stimulated amino acid incorporation, and this effect was mimicked by both dibutyryl cAMP and IBMX, a phosphodiesterase inhibitor. Although insulin further stimulated incorporation in the presence of isoproterenol and IBMX, no additional increase in the rate of synthesis was observed after stimulation by dibutyryl cAMP. High concentrations of carbamylcholine, a cholinergic agonist, inhibited both basal and insulin-stimulated incorporation. At low concentrations, however, carbamylcholine stimulated synthesis, and the effects of insulin and carbamylcholine were additive. A23187, a calcium ionophore, also inhibited 3H-leucine incorporation and insulin stimulation, but in contrast to carbamylcholine, low concentrations of A23187 neither inhibited nor enhanced the rate of synthesis. Thus, protein synthesis in the rat submandibular gland is regulated by both insulin and neurotransmitters. Whereas beta-adrenergic stimulation appears to be mediated through cAMP, the intracellular signals mediating the actions of insulin and cholinergic agonists remain to be elucidated.     

Changes in cardiac structure and function in rats immunized by angiotensin type 1 receptor peptides

Angiotensin II (Ang II) is known to induce cardiomyocyte hypertrophy by activating the Ang II type 1 (AT1) receptor. Some studies have demonstrated that the autoantibodies against angiotensin AT1 receptor (AT1-AAs) cause functional effects, which is similar to those observed for the natural agonist Ang II. In this study, we investigated the effects of AT1-AAs on cardiomyocytes' structure and function. Male Wistar rats were immunized with synthetic peptides corresponding to the second extracellular loop of AT1 receptor and Freund's adjuvant. The titers of AT1-AAs in rat serum were detected by enzyme-linked immunosorbent assay every week. Hemodynamic analysis and heart weight (HW) indices were measured on the 4th and 8th months after initial immunization, respectively. Cultured neonatal rat cardiomyocytes were used to observe the hypertrophic effects of AT1-AAs. Results showed that systolic blood pressure and heart rate were significantly increased, the titers of AT1-AAs were also increased after 4 weeks of initial immunization. Compared with control group, the HW/body weight (BW) and left ventricular weight/BW of immunized rats were increased significantly and cardiac function was enhanced compensatively. The cultured neonatal rat cardiomyocytes respond to AT1-AAs stimulation with increased (3)H-leucine incorporation and cell surface area in a dose-dependent manner. These results suggest that the AT1-AAs have an agonist effect similar to Ang II in hypertrophy of cardiomyocytes in vivo and in vitro. AT1-AAs are involved in the pathogenesis of cardiovascular diseases and hypertension.     

脂肪干细胞与间充质干细胞体外诱导分化为心肌细胞的差别

本文旨在探讨脂肪干细胞(adipose-derived stem cells, ASCs)和骨髓间充质干细胞(mesenchymal stem cells, MSCs)在组织含量、体外培养和诱导分化为心肌细胞方面的差别.ASCs从新西兰白兔皮下脂肪组织提取,MSCs从大鼠四肢长骨骨髓提取,体外培养扩增,免疫细胞学方法鉴定.采用细胞集落形成法检测组织中干细胞的含量.将不同代的干细胞用不同浓度的5-氮胞苷诱导,观察其形态变化,免疫细胞化学方法检测诱导后细胞是否转化为心肌细胞.结果显示,体外培养的ASCs呈短梭形,分布均匀,生长迅速,细胞形态单一、稳定.MSCs原代生长非常缓慢,呈簇生长,细胞纯度偏低,容易混杂其它细胞类型,传代细胞容易分化和老化.脂肪组织中ASCs含量显著高于骨髓中MSCs含量,且前者含量受年龄影响小.5-氮胞苷诱导ASCs分化为心肌细胞的有效浓度为6～9μmol/L,而MSCs在3～15μmol/L 5-氮胞苷诱导下可见心肌细胞形成.ASCs诱导分化的心肌细胞呈球形细胞团,MSCs分化的心肌细胞呈条形或棒状,其心肌细胞分化率低于ASCs.幼年动物MSCs的组织含量和心肌细胞分化率均高于老年动物,而ASCs受动物年龄影响较小.结果表明,ASCs在组织含量、细胞纯度、生长速度和心肌细胞分化率等方面均明显优于骨髓MSCs,在心肌细胞再生方面较MSCs具有更大的优势.     

Clusterin: a protective mediator for ischemic cardiomyocytes?

We examined the relationship between clusterin and activated complement in human heart infarction and evaluated the effect of this protein on ischemic rat neonatal cardiomyoblasts (H9c2) and isolated adult ventricular rat cardiomyocytes as in vitro models of acute myocardial infarction. Clusterin protects cells by inhibiting complement and colocalizes with complement on jeopardized human cardiomyocytes after infarction. The distribution of clusterin and complement factor C3d was evaluated in the infarcted human heart. We also analyzed the protein expression of clusterin in ischemic H9c2 cells. The binding of endogenous and purified human clusterin on H9c2 cells was analyzed by flow cytometry. Furthermore, the effect of clusterin on the viability of ischemically challenged H9c2 cells and isolated adult ventricular rat cardiomyocytes was analyzed. In human myocardial infarcts, clusterin was found on scattered, morphologically viable cardiomyocytes within the infarcted area that were negative for complement. In H9c2 cells, clusterin was rapidly expressed after ischemia. Its expression was reduced after reperfusion. Clusterin bound to single annexin V-positive or annexin V and propidium iodide-positive H9c2 cells. Clusterin inhibited ischemia-induced death in H9c2 cells as well as in isolated adult ventricular rat cardiomyocytes in the absence of complement. We conclude that ischemia induces the upregulation of clusterin in ischemically challenged, but viable, cardiomyocytes. Our data suggest that clusterin protects cardiomyocytes against ischemic cell death via a complement-independent pathway.